Ubs Group Ag Nuvectis Pharma, Inc. Transaction History

Ubs Group Ag

$555 Billion
Q2 2025

A detailed history of Ubs Group Ag transactions in Nuvectis Pharma, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 10,258 shares of NVCT stock, worth $62,676. This represents 0.0% of its overall portfolio holdings.

Number of Shares

10,258

Previous 111,520 90.8%

Holding current value

$62,676

Previous $1.09 Million 93.02%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$7.47 - $10.96 $756,427 - $1.11 Million	-101,262 Reduced 90.8%	10,258 $76,000
Q1 2025 May 13, 2025	BUY	$5.37 - $10.46 $584,529 - $1.14 Million	108,851 Added 4078.34%	111,520 $1.09 Million
Q4 2024 Feb 14, 2025	BUY	$4.52 - $10.98 $12,014 - $29,184	2,658 Added 24163.64%	2,669 $14,000
Q3 2024 Nov 14, 2024	SELL	$6.16 - $7.23 $12 - $14	-2 Reduced 15.38%	11 $0
Q2 2024 Aug 13, 2024	SELL	$5.98 - $8.25 $45,489 - $62,757	-7,607 Reduced 99.83%	13 $0
Q1 2024 May 13, 2024	SELL	$6.69 - $11.0 $2,943 - $4,840	-440 Reduced 5.46%	7,620 $62,000
Q4 2023 Feb 09, 2024	BUY	$7.85 - $11.78 $33,629 - $50,465	4,284 Added 113.45%	8,060 $67,000
Q3 2023 Nov 09, 2023	SELL	$12.89 - $16.29 $2,616 - $3,306	-203 Reduced 5.1%	3,776 $48,000
Q2 2023 Aug 11, 2023	BUY	$12.62 - $18.4 $50,214 - $73,213	3,979 New	3,979 $63,000
Q3 2022 Nov 10, 2022	BUY	$7.09 - $13.0 $1,120 - $2,054	158 Added 254.84%	220 $2,000
Q2 2022 Aug 10, 2022	SELL	$7.02 - $20.44 $554 - $1,614	-79 Reduced 56.03%	62 $1,000
Q1 2022 May 16, 2022	BUY	$3.25 - $9.1 $458 - $1,283	141 New	141 $1,000

Others Institutions Holding NVCT

# of Institutions

Shares Held

3.21M

Call Options Held

44.5K

Put Options Held

50.1K

View Full List

About Nuvectis Pharma, Inc.

Ticker NVCT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 14,642,500
Market Cap $89.5M
Description
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src...

More about NVCT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account